Antihypertensive utility of perindopril in a large, general practice-based clinical trial.

Stevo Julius, Jay N. Cohn, Joel Neutel, Michael Weber, Prasad Turlapaty, Yannan Shen, Victor Dong, Alicia Batchelor, Hjalmar Lagast

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume6
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Perindopril
General Practice
Antihypertensive Agents
Clinical Trials
Blood Pressure
Physicians
Guidelines
Hypertension
Safety
Therapeutics

Cite this

Antihypertensive utility of perindopril in a large, general practice-based clinical trial. / Julius, Stevo; Cohn, Jay N.; Neutel, Joel; Weber, Michael; Turlapaty, Prasad; Shen, Yannan; Dong, Victor; Batchelor, Alicia; Lagast, Hjalmar.

In: Journal of clinical hypertension (Greenwich, Conn.), Vol. 6, No. 1, 01.2004, p. 10-17.

Research output: Contribution to journalArticle

Julius, Stevo ; Cohn, Jay N. ; Neutel, Joel ; Weber, Michael ; Turlapaty, Prasad ; Shen, Yannan ; Dong, Victor ; Batchelor, Alicia ; Lagast, Hjalmar. / Antihypertensive utility of perindopril in a large, general practice-based clinical trial. In: Journal of clinical hypertension (Greenwich, Conn.). 2004 ; Vol. 6, No. 1. pp. 10-17.
@article{7966afd6b078402cb7715afb41f2e028,
title = "Antihypertensive utility of perindopril in a large, general practice-based clinical trial.",
abstract = "The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8{\%} patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.",
author = "Stevo Julius and Cohn, {Jay N.} and Joel Neutel and Michael Weber and Prasad Turlapaty and Yannan Shen and Victor Dong and Alicia Batchelor and Hjalmar Lagast",
year = "2004",
month = "1",
doi = "10.1111/j.1524-6175.2004.02440.x",
language = "English (US)",
volume = "6",
pages = "10--17",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Antihypertensive utility of perindopril in a large, general practice-based clinical trial.

AU - Julius, Stevo

AU - Cohn, Jay N.

AU - Neutel, Joel

AU - Weber, Michael

AU - Turlapaty, Prasad

AU - Shen, Yannan

AU - Dong, Victor

AU - Batchelor, Alicia

AU - Lagast, Hjalmar

PY - 2004/1

Y1 - 2004/1

N2 - The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.

AB - The authors evaluated, in a community-based open-label trial, the effectiveness and safety of perindopril in 13,220 US hypertensive patients and studied how physicians adhere to hypertension treatment guidelines. Patients received perindopril 4 mg q.d. for 6 weeks. Based on physicians perception of blood pressure response, the patient was either maintained on 4 mg or the dose was increased to 8 mg for an additional 6 weeks. From baseline to week 12, the mean sitting blood pressure significantly declined from 156.9/94.5 mm Hg to 139.2/84.0 mm Hg. Further dose titration resulted in a clinically significant reduction in blood pressure in all patients with inadequate response on 4 mg at week 6. Blood pressure control (<140/<90 mm Hg) was achieved at 12 weeks in 48.8% patients. The subpopulation analyses demonstrated that perindopril monotherapy was effective in both men and women, in patients of all ethnicities, and in patients <65 and > or =65 years of age. Perindopril was safe and well tolerated in all hypertensive subgroups including high-risk patients. Physicians were more attuned to controlling diastolic than systolic blood pressure, and their adherence to the treatment guidelines was found to be not optimal.

UR - http://www.scopus.com/inward/record.url?scp=1642428445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642428445&partnerID=8YFLogxK

U2 - 10.1111/j.1524-6175.2004.02440.x

DO - 10.1111/j.1524-6175.2004.02440.x

M3 - Article

C2 - 14724419

AN - SCOPUS:1642428445

VL - 6

SP - 10

EP - 17

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

SN - 1524-6175

IS - 1

ER -